Darren R Hargrave
Overview
Explore the profile of Darren R Hargrave including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OHare P, Cooney T, de Blank P, Gutmann D, Kieran M, Milde T, et al.
Neuro Oncol
. 2024 May;
26(8):1357-1366.
PMID: 38743009
Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection is not possible, is one of a chronic disease with periods of...
2.
Gill S, Rose H, Wilson M, Rodriguez Gutierrez D, Worthington L, Davies N, et al.
NMR Biomed
. 2024 Feb;
37(5):e5101.
PMID: 38303627
H-magnetic resonance spectroscopy (MRS) has the potential to improve the noninvasive diagnostic accuracy for paediatric brain tumours. However, studies analysing large, comprehensive, multicentre datasets are lacking, hindering translation to widespread...
3.
Bouffet E, Hansford J, Garre M, Hara J, Plant-Fox A, Aerts I, et al.
N Engl J Med
. 2023 Sep;
389(12):1108-1120.
PMID: 37733309
Background: Detection of the V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination...
4.
Hargrave D, Terashima K, Hara J, Kordes U, Upadhyaya S, Sahm F, et al.
J Clin Oncol
. 2023 Aug;
41(33):5174-5183.
PMID: 37643378
Purpose: V600 mutation is detected in 5%-10% of pediatric high-grade gliomas (pHGGs), and effective treatments are limited. In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity...
5.
Fangusaro J, Cefalo M, Garre M, Marshall L, Massimino M, Benettaib B, et al.
Front Oncol
. 2021 Jun;
11:660892.
PMID: 34168987
Introduction: Treatment of recurrent primary pediatric brain tumors remains a major challenge, with most children succumbing to their disease. We conducted a prospective phase 2 study investigating the safety and...
6.
Clarke M, Mackay A, Ismer B, Pickles J, Tatevossian R, Newman S, et al.
Cancer Discov
. 2020 Apr;
10(7):942-963.
PMID: 32238360
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases...
7.
Rodriguez Gutierrez D, Jones C, Varlet P, Mackay A, Warren D, Warmuth-Metz M, et al.
Clin Cancer Res
. 2020 Jan;
26(8):1856-1865.
PMID: 31924736
Purpose: The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The...
8.
Hargrave D, Bouffet E, Tabori U, Broniscer A, Cohen K, Hansford J, et al.
Clin Cancer Res
. 2019 Dec;
25(24):7303-7311.
PMID: 31811016
Purpose: Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor. Patients with V600 mutation-positive pLGG may benefit from treatment with dabrafenib. Part 2 of a phase I/IIa study,...
9.
Manias K, Harris L, Davies N, Natarajan K, MacPherson L, Foster K, et al.
Pediatr Radiol
. 2018 Aug;
48(11):1630-1641.
PMID: 30062569
Background: A tool for diagnosing childhood cerebellar tumours using magnetic resonance (MR) spectroscopy peak height measurement has been developed based on retrospective analysis of single-centre data. Objective: To determine the...
10.
Carceller F, Bautista F, Jimenez I, Hladun-Alvaro R, Giraud C, Bergamaschi L, et al.
J Neurooncol
. 2017 Dec;
137(1):83-92.
PMID: 29236237
Central nervous system (CNS) tumors are a leading cause of death in pediatric oncology. New drugs are desperately needed to improve survival. We evaluated the outcome of children and adolescents...